Адаптована клінічна настанова, заснована на доказах (стр. 59 )

446. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 2006;31: 823–4.

447. Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007;33:787–802.

448. Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004;6:88–90.

449. Weenig RH, Davis MDP, Dahl PR, et al. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J J Med 2002;347:1412–8.

450. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;333:181–4.

451. Juillerat P, Mottet C, Pittet V, et al. Extraintestinal manifestations of Crohn's disease. Digestion 2007;76:141–8.

452. Matis WL, Ellis CN, Griffiths CE, et al. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992;128: 1060–4.

453. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease:effects of TNF-a blockade with infliximab. Scand J Gastroenterol 2002;37:1108–10.

454. Regueiro M, Valentine J, Plevy S, et al. Infliximab for the treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821–6.

455. Brooklyn TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, doubleblind, placebo controlled trial. Gut 2006;55:505–9.

456. Poritz LS, Lebo MA, Bobb AD, et al. Management of peristomal pyoderma gangrenosum. J Am Coll Surg 2008;206:311–5.

457. Cohen PR. Sweet's syndrome — a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007;2:34.

458. Travis SPL, Innes N, Davies MG, et al. Sweet's syndrome: an unusual cutaneous manifestation of Crohn's disease and ulcerative colitis. Eur J Gastroenterol Hepatol 1997;9:715–20.

459. Ytting H, Vind I, Bang D, et al. Sweet's syndrome — an extraintestinal manifestation in inflammatory bowel disease. Digestion 2005;72:195–200.

460. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004;10: 135–9.

461. Vitellas KM, Enns RA, Keogan MT, et parison of MR cholangiopancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis. Am J Roentgenol 2002;178:327–34.

462. Talwalkar JA, Angulo P, Johnson CD, Petersen BT, Lindor KD. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004;40:39–45.

463. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006;26:52–61.

464. Lindor KD, The Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic acid Study Group. Ursodiol for primary sclerosing cholangitis. N Eng J Med 1997;336:691–5.

465. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of highdose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900–7.

466. Sjoqvist U, Tribukait B, Ost A, et al. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 2004;24:3121–7.

467. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus, a treatment for primary sclerosing cholangitis: results of an open label preliminary trial. Am J Gastroenterol 1995;90: 455–9.

468. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a populationbased cohort study. Thromb Haemost 2001;85:430–4.

469. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53:542–8.

470. Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007;21:507–11.

471. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1–9.

472. Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 2007;102:174–86.

473. Task Force on Pulmonary Embolism, European Society of Cardiology. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000;21:1301–36.

474. Qaseem A, Snow V, Barry P, et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline fromtheAmericanAcademyofFamily Physicians and the American College of Physicians. Ann Intern Med 2007;146:454–8.

475. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guideline (8th edition). Chest 2008;133:454–545.

476. Cardiovascular Disease Educational and Research Trust, Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum, International Surgical Thrombosis Forum, International Union of Angiology, Union Internationale de Phébologie. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006;25:101–61.

477. Shen J, Ran ZH, Tong JL, et al. Meta-analysis: the utility and safety of heparin in the treatment of acitve ulcerative colitis. Aliment Pharmacol Ther 2007;26:653–63.

478. Geerts WH, Bergquist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physiciansevidence-based clinical practice guidelines (8th edition). Chest 2008;133:353–81.

479. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symtomatic venous thromboemblism in hospitalized medical patients. Ann Int Med 2007;146:278–88.

480. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793–800.

481. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboemblism in hospitalized patients with acute medical illness. Arch Intern Med 2004;164:963–8.

482. Hilsden RJ, Verhoef MJ, Best A, Pocobelli plementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol 2003;98:1563–8.

483. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 2005;11:287–95.

484. Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use? Am J Gastroenterol 2004;99:889–93.

485. Dick A, Keady S, Mohamed F, Brayley S, et al. Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. Aliment Pharmacol Ther 2003;17:571–5.

486. Langmead L, Rampton DS. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:341–9.485. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001;39:11–7 German.

488. Joos S, Wildau N, Kohnen R, et al. Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol 2006;41:1056–63.

489. Joos S, Brinkhaus B, Maluche C, et al. Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion 2004;69:131–9. 100 G. Van Assche et al.

490. Belluzzi A, Brignola C, Campieri M, et al. Effect of an entericcoated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557–60.

491. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA 2008;299: 1690–7.

492. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;1:CD006320.

European evidence based consensus for endoscopy in inflammatory bowel disease

Journal of Crohn's and Colitis (2013) 7, 982–1018

1. Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006;63:558–65.

2. Bourreille A, Ignjatovic A, Aabakken L, Loftus Jr EV, Eliakim R, Pennazio M, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009;41:618–37.

3. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979–83.

4. http://www. /mod_product/design/files/CEBM-Levelsof- Evidence-2.1.pdf.

5. Manes G, Imbesi V, Ardizzone S, Cassinotti A, Bosani M, Massari A, et al. Appropriateness and diagnostic yield of colonoscopy in the management of patients with ulcerative colitis: a prospective study in an open access endoscopy service. Inflamm Bowel Dis 2008;14:1133–8.

6. Markowitz J, Kahn E, Grancher K, Hyams J, Treem W, Daum F. Atypical rectosigmoid histology in children with newly diagnosed ulcerative colitis. Am J Gastroenterol 1993;88:2034–7.

7. Robert ME, Skacel M, Ullman T, Bernstein CN, Easley K, Goldblum JR. Patterns of colonic involvement at initial presentation in ulcerative colitis: a retrospective study of 46 newly diagnosed cases. Am J Clin Pathol 2004;122:94–9.

8. Robert ME, Tang L, Hao LM, Reyes-Mugica M. Patterns of inflammation in mucosal biopsies of ulcerative colitis: perceived differences in pediatric populations are limited to children younger than 10 years. Am J Surg Pathol 2004;28: 183–9.